RxDoctor Payments DataLook up a doctor →

Tarra Nelson, NP

Nurse Practitioner · Cumming, GANPI 1295722973

Payments from drug & device makers

$13,006in general payments, 2019–2025

Across 632 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • AbbVie$2K
  • Biogen$757
  • Teva Pharmaceuticals USA, Inc.$733
  • Argenx US, Inc.$679
  • SK Life Science, Inc.$601
  • plus $7K from 50 others

What the payments were for

  • Speaking & faculty fees$110%
  • Food & beverage$12,88499%
  • Education$1121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,006 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$44,856
Medicare patients
266
Services billed
524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine63$740,259
GocovriAmantadine Hcl17$83,626
Gamunex-CImmune Globul G/Gly/Iga Avg 4618$83,072
NuedextaDextromethorphan Hbr/Quinidine31$59,791
BriviactBrivaracetam39$56,554
Droxidopa35$48,428
UbrelvyUbrogepant25$39,309
NamzaricMemantine Hcl/Donepezil Hcl27$24,630
Memantine Hcl ErMemantine Hcl199$22,037
NeuproRotigotine17$17,306
Ajovy AutoinjectorFremanezumab-Vfrm14$17,086
EliquisApixaban19$15,035
Rasagiline Mesylate79$11,638
RytaryCarbidopa/Levodopa17$8,890
BelsomraSuvorexant18$8,693

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$733$740,25963 claims
MDD US Operations, LLCGocovri$76$83,62617 claims
Grifols USA, LLCGamunex-C$36$83,07218 claims
UCB, Inc.Briviact, Neupro$1,667$73,86056 claims
AbbVieUbrelvy, Namzaric$1,646$63,93952 claims
Avanir Pharmaceuticals, Inc.Nuedexta$370$59,79131 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$353$18,387102 claims
PfizerEliquis$549$15,03519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →